499 results about "Mouse Heart" patented technology

An image guided navigation system for navigating a region of a patient includes an imaging device, a tracking device, a controller, and a display. The imaging device generates images of the region of a patient. The tracking device tracks the location of the instrument in a region of the patient. The controller superimposes an icon representative of the instrument onto the images generated from the imaging device based upon the location of the instrument. The display displays the image with the superimposed instrument. The images and a registration process may be synchronized to a physiological event. The controller may also provide and automatically identify an optimized site to navigate the instrument to.

Systems and methods for providing communications between an external device and first and second leadless pacemakers (LPs) located in a heart are provided. A method includes receiving first and second event messages from the first and second LPs, the first and second event messages received at different points in time at the external device, determining the signal strengths of the first and second event messages, respectively, as received at the external device, adjusting first and second LP discrimination thresholds based on the received signal strengths of the first and second event messages, respectively, and utilizing the first and second LP discrimination thresholds to identify which of the first and second LP transmits subsequent event messages, in order for the external device to independently communicate with the first and second LPs.

The present invention provides methods for screening drugs inhibiting the expression of OSF-2 gene or the production or function of the protein encoded thereby and therapeutic agents for heart failure having such effects. Useful methods for diagnosing heart failure can be provided by monitoring the expression or variation of said gene or the production of the protein encoded thereby. The present invention also provides transgenic animals with forced expression of OSF-2 gene and methods for studying changes in gene expression or protein production or the functions of various genes or proteins with the progress of the pathology of heart failure using them and novel therapeutic agents for heart failure.

An apical implantation mitral valve balloon closure plate blocking body and an implantation method, for human heart repair are disclosed. A balloon closure plate made from an elastic plastic material which may be filled with a gas or a curable liquid is implanted via a small incision on the left side of the chest, enters the left ventricle via the apex, and is placed and fixed at a backflow hole position of a front and rear leaflet closure point of the mitral valve. The present disclosure treats diseases such as functional mitral valve regurgitation, and the success rate for repairing functional mitral valve backflow is more than 90%.

The invention relates to a materialized heart 3D model manufacturing method capable of achieving internal and external structures. The method can overcome the defects in the prior art. The method includes the steps that (1) the heart part of a patient is scanned to obtain medical image data to form a DICOM file; (2) the DICOM file obtained in the step (1) is identified through Mimics software and stored to form a computer-identified .mcs file; (3) different data templates are extracted from the software; (4) the templates, with cavity structures or incomplete images or unclear boundaries, obtained in the step (3) are processed to be made clear and complete; (5) a needed template is formed by adding or deleting or separating or combining the templates; (6) a 3D image formed in the step (5) is processed to enable the exterior of the 3D image to be smooth and interior image templates to be complete to form an STL file; (7) data processed in the step (6) are input in a 3D laser printer, and accordingly a heart model is printed. According to the method, heart models with clear and complete structures can be obtained, and the success rate of heart operations can be greatly increased.

Apparatus and associated methodology for monitoring correlatable anatomical electrical and sound signals, such as electrical and audio signals produced by human heart activity, including (a) attaching to a selected, common anatomical site ECG (or other) electrode structure, and a multi-axial sound sensor, and (b) simultaneously collecting from adjacent that site both ECG(or other)-electrical and sound signals, where such sound signals arrive adjacent the site along multiple, angularly intersecting axes.

A system and method for recording and depicting ultrasound images of a moving object are disclosed. In a preferred embodiment, ultrasound images are acquired as the field of view of an ultrasound probe is advanced across the tissues of interest during a resting period between periods of relatively large-scale heart cycle motion. A series of images acquired during a particular resting period may be represented as a three-dimensional volume image, and the comparison of volume images from adjacent cardiac resting periods enables three-dimensional volume image modulation analysis which may be presented for a user as a moving volume image of the objects of interest within the field of view.

An artificial valve is delivered percutaneously in the form of a hollow inflatable shell, which is later filled in situ with a suitable elastomer, similar to inflating a balloon. Since the shell is a flexible and mostly hollow balloon, it can be compressed and transported via a relatively small catheter. In order to inflate to the correct shape the hollow shell requires some ties between its walls. These ties are formed from a low density open cell foam or a specialized manufacturing process. The valve can combine elements with different stiffness as well as different materials. A positioning balloon can also be used in the process of placing the valve. The invention is particularly suited for cardiac valves but can be used for other artificial valves.

A method is for production of tomographic section images, in particular X-ray CT images, of an at least partially periodically moving examination object with periodically changing movement and rest phases, preferably of a heart of a living being. A number of focus detector combinations are used, with the time resolution of the CT scanner being significantly increased by supplementary combination of detector data in the correct phase. On the one hand, a number of focus detector combinations which scan an examination object at the same time are used; and on the other hand a number of adjacent movement cycles of a periodically moving examination object are performed.

A heart valve prosthesis includes an annulus and a closing element having three leaflets. Hinge mechanisms are provided for attaching each leaflet to a top region of an interior surface of the annulus. In one example, the leaflets have convexo-concave surfaces and a non-uniform thickness. In another example, the top region of the interior surface has two sets of ledges which can be formed by intersecting three pairs of cylindrical surfaces. Ledges within each set are evenly spaced about the interior surface, a ledge in one set alternating with a ledge in the other set. In a further example, a bottom region of the interior surface is formed by intersecting three cylindrical surfaces.

A method for treating a subject afflicted with a cardiac disorder, in vivo, comprising (i) producing a solution comprising media conditioned from the culture of cells, in vitro, and (ii) administering the solution of step (i) to the subject, thereby treating the cardiac disorder in the subject. Methods for determining whether an agent stimulates or inhibits myocyte proliferation.

The invention features an optically-controlled biological device that includes a biological component comprising a non-excitable cell expressing a light-gated ion channel protein and capable of forming gap junction channels with a target cell, and an optical stimulation unit.

A testing system for testing a prosthetic valve. The system includes a housing having a main channel defines a circuitous flow path for a fluid. The solid housing also includes a chamber which in turn includes a piston having an opening at the bottom end. The piston moves in a reciprocating motion within the chamber. Further, a holding mechanism, for holding a prosthetic valve, is positioned within the main channel at either or both sides of the chamber, or within the opening in the piston. A user of the device may selectively control a flow path of the fluid between 1). having the fluid flow through the prosthetic valve installed in the piston, and 2). having no fluid passing though the piston.

Compositions and methods are provided for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns, or both, in a human or animal subject comprising: one or more pharmacologically active agents that causes at least one of IKr channel inhibition or QT prolongation by inhibiting the activity of an ether-a-go-go-related gene (hERG); and one or more liposomes, wherein the liposomes are empty liposomes and administered prior to, concomitantly, or after administration of the pharmacologically active agent.

Novel adeno-associated virus (AAV) vectors in nucleotide and amino acid forms and uses thereof are provided. The isolates show specific tropism for certain target tissues, such as blood stem cells, liver, heart and joint tissue, and may be used to transduce stem cells for introduction of genes of interest into the target tissues. Certain of the vectors are able to cross tightly controlled biological junctions, such as the blood-brain barrier, which open up additional novel uses and target organs for the vectors, providing for additional methods of gene therapy and drug delivery.

The invention relates to a surface modification method and application of a porous material. The surface modification method of the porous material comprises the following steps: soaking the porous material in a zwitter-ion reaction solution and fully wetting the porous material; and taking out the wetted porous material and carrying out crosslinking to obtain a zwitter-ion hydrogel modified porous material. The zwitter-ion reaction solution comprises 10-50% of zwitter-ion monomers, 0.01-5% of a crosslinking agent, 0.01-0.5% of an initiator and a solvent. The method is a universal surface modification method; a modification process is simple and convenient; a modified coating can be stable in a complicated biotic environment for a long time, the modified surface has a certain pore structure, therefore, the porous material loaded with a water-soluble and hydrophobic drug can be modified, and the purposes of releasing the drug in a sustained manner and improving the bioavailability of the drug are achieved; and the surface modification method can be used for modifying surfaces of porous metal or alloy, and is applied to repair or replacement of materials such as skin, cardiac valves,bones, cartilages or vascular tissues.

This document discusses, among other things a cardiac lead with first and second electrodes electrically interconnected by back-to-back diodes or another conductivity control device. During sensing of intrinsic electrical heart signals, these electrodes are isolated from each other by the conductivity control device. This reduces noise during sensing. During pacing or defibrillation, these electrodes are electrically connected to each other by the conductivity control device. When used in common as a return path electrode, this avoids unintentional stimulation of the heart at the return path electrode instead of at the stimulating electrode. The electrodes can also share a common conductor from one of the electrodes back to a proximal end of the lead.

The invention includes a zebrafish assay for cardiac response.

The present invention relates to screens for compounds that can induce stem cell differentiation. In addition, isoxazoles and sulfonyl hydrazones are identified as general classes of compounds that can induce differentiation of stem cells into cells of neuronal and cardiac fate, respectively.

The present invention relates to stabilised <99m>Tc radiopharmaceutical compositions, which include both a radioprotectant and one or more antimicrobial preservative(s), and hence have an extended lifetime of use. The radioprotectant is ascorbic acid, para-aminobenzoic acid, gentisic acid or a salt thereof with a biocompatible cation, and the antimicrobial preservative is one or more compound from the paraben series of preservatives. The invention is particularly useful for cationic, lipophilic <99m>Tc heart imaging agents such as Myoview(TM).

The present invention provides peptide-based peroxidase inhibitors having the formula AA1-AA2-AA3, wherein AA1 is a positively charged, negatively charged or neutral amino acid, AA2 is a redox active amino acid, and AA3 is an amino acid possessing a reducing potential such that AA3 is capable of undergoing a redox reaction with a radical of amino acid AA2 or a retro or retro-inverso analog thereof. The result of such a combination is a highly effective inhibitor of peroxidase activity that has potent anti-inflammatory properties in widely diverse models of vascular disease and injury. Exemplary tripeptides effectively inhibit peroxidase mediated LDL oxidation, increase vasodilation in SCD mice, inhibit eosinophil infiltration and collagen deposition in asthma mice, inhibit acute lung injury, and decrease ischemic injury of the heart.

Described embodiments are directed toward prosthetic valve leaflets of particular configurations that control bending character. In embodiments provided herein, a valve leaflet is provided with a planar zone that is bounded at a planar zone base by a straight line, wherein the leaflet is operable to bend along a base of the planar zone.

A hybridoma producing a monoclonal antibody recognizing the C-terminus of human brain natriuretic peptide (hBNP) was cultivated in a medium or the abdominal cavity of a mouse to recover the monoclonal antibody from the medium or ascites accumulated in the abdominal cavity. An immunoassay for hBNP was established using the monoclonal antibody. The immunoassay for hBNP of the invention is so sensitive that the minimum detection limit is 1 pg / ml and can therefore determine the hBNP level in blood plasma directly, without the extraction of hBNP from blood plasma. It is useful for diagnosing diseases such as hypertension and the like, and states of the heart, kidney, and the like by using the increase / decrease of the hBNP level as an index.